NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER) on behalf of Omeros stockholders. Our investigation concerns whether Omeros has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On October 1, 2021, Omeros announced that the U.S. Food and Drug Administration (“FDA”) had identified deficiencies with the Company’s Biologics License Application for its drug candidate narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), which “preclude discussion of labeling and post-marketing requirements/commitments at this time.” Though the “FDA did not provide specific details of the deficiencies in its notification[,]” the Company stated that it "does not currently expect any resolution to occur by the October 17, 2021 target action date under the Prescription Drug User Fee Act (PDUFA).”
On this news, Omeros’s stock price fell $5.25 per share, or 38%, to close at $8.54 per share on October 1, 2021, thereby injuring investors.
If you purchased or otherwise acquired Omeros shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
